TY - JOUR
T1 - Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe
T2 - An International Simulated-Use Study (PRESTO)
AU - Adelman, Daphne
AU - Truong Thanh, Xuan Mai
AU - Feuilly, Marion
AU - Houchard, Aude
AU - Cella, David
N1 - Funding Information:
Sponsorship for this study and the journal’s Open Access and Rapid Service fee were funded by Ipsen.
Funding Information:
The authors thank all nurses who participated in the study. The authors would also like to thank the contract research organisation, IQVIA, for its contribution to study recruitment and conduct of the study sessions; in particular, Mr Paul Williams (Lead Statistician, Real World Solutions, IQVIA), who led the design and scientific aspects, analysis, and interpretation and reporting of results, and Dr Laurie Batchelder (Lead Medical Writer, Real World Solutions, IQVIA), who substantially contributed to the design of the survey and protocol, statistical analysis plan and discussion of the report. Sponsorship for this study and the journal?s Open Access and Rapid Service fee were funded by Ipsen. The authors thank Jacqueline Harte and Helen Marshall of Watermeadow Medical, an Ashfield company, for providing medical writing and editorial support, which was sponsored by Ipsen in accordance with Good Publication Practice guidelines. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors contributed to the study conception/design, or acquisition, analysis, and/or interpretation of data. All authors were involved in drafting and/or critical revision of the manuscript for intellectual content and provided final approval for publication. Ipsen was involved in the study design, conduct, and analysis of this study, and provided funding for the medical writing support to develop this publication. Study recruitment and conduct of the study sessions was managed by the contract research organisation, IQVIA. An abstract has been submitted for presentation at ENETS, Barcelona, Spain, 11?13th March 2020. DA received: consultancy fees from Pfizer and Novo Nordisk; and has served on an advisory board for Ipsen, Crinetics and Novo Nordisk. DC received: consultancy fees from Ipsen and Novartis; and grant support from Ipsen and Novartis. XMTT, MF and AH are employees of Ipsen. As this study was not a clinical trial and no patients were involved, institutional review board approvals were not required. This study followed the recommendations from the International Society for Pharmacoepidemiology, Good Pharmacoepidemiology Practice Guidelines, April 2007.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Introduction: Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes. PRESTO aimed to assess preferences of nurses between the LAN new syringe and the octreotide long-acting release (LAR) syringe. Methods: PRESTO, a multinational, multicentre, prospective, noninterventional, simulated-use study, enrolled nurses with ≥ 2 years’ experience injecting LAN and/or octreotide LAR in patients with NETs and/or acromegaly. Nurses administered injections into pads using the LAN new syringe and octreotide LAR syringe in a randomised sequence. In an anonymous web-based questionnaire, nurses reported their overall preference (‘strong’ or ‘slight’; primary endpoint) and rated and ranked the importance of nine attributes for each syringe (1 [not at all] to 5 [very much]). Results: Overall, 90 nurses attended sessions and completed valid questionnaires. Most nurses (97.8%) expressed a preference (85.6% ‘strong’, 12.2% ‘slight’) for the LAN new syringe versus the octreotide LAR syringe (P < 0.0001). Attribute performance ratings (1 [not at all] to 5 [very much]) were consistently higher for the LAN new syringe versus the octreotide LAR syringe, with the greatest differences in ‘fast administration’ and ‘confidence the syringe will not be clogged’ (mean difference [SD]: 2.6 [1.2] and 2.3 [1.5], respectively; P < 0.0001). The attribute ranked most important was ‘confidence the syringe will not be clogged’ (24.4%); least important was ‘convenience of syringe format, including packaging, from preparation to injection’ (34.4%). Conclusions: Nurses preferred the user experience of the LAN new syringe compared with the octreotide LAR syringe, with a particular preference for attributes related to product delivery with the LAN new syringe. Graphical Abstract: [Figure not available: see fulltext.].
AB - Introduction: Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes. PRESTO aimed to assess preferences of nurses between the LAN new syringe and the octreotide long-acting release (LAR) syringe. Methods: PRESTO, a multinational, multicentre, prospective, noninterventional, simulated-use study, enrolled nurses with ≥ 2 years’ experience injecting LAN and/or octreotide LAR in patients with NETs and/or acromegaly. Nurses administered injections into pads using the LAN new syringe and octreotide LAR syringe in a randomised sequence. In an anonymous web-based questionnaire, nurses reported their overall preference (‘strong’ or ‘slight’; primary endpoint) and rated and ranked the importance of nine attributes for each syringe (1 [not at all] to 5 [very much]). Results: Overall, 90 nurses attended sessions and completed valid questionnaires. Most nurses (97.8%) expressed a preference (85.6% ‘strong’, 12.2% ‘slight’) for the LAN new syringe versus the octreotide LAR syringe (P < 0.0001). Attribute performance ratings (1 [not at all] to 5 [very much]) were consistently higher for the LAN new syringe versus the octreotide LAR syringe, with the greatest differences in ‘fast administration’ and ‘confidence the syringe will not be clogged’ (mean difference [SD]: 2.6 [1.2] and 2.3 [1.5], respectively; P < 0.0001). The attribute ranked most important was ‘confidence the syringe will not be clogged’ (24.4%); least important was ‘convenience of syringe format, including packaging, from preparation to injection’ (34.4%). Conclusions: Nurses preferred the user experience of the LAN new syringe compared with the octreotide LAR syringe, with a particular preference for attributes related to product delivery with the LAN new syringe. Graphical Abstract: [Figure not available: see fulltext.].
KW - New syringe
KW - Nurse preference
KW - Simulated injection
KW - Somatostatin analogue
UR - http://www.scopus.com/inward/record.url?scp=85081883742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081883742&partnerID=8YFLogxK
U2 - 10.1007/s12325-020-01255-8
DO - 10.1007/s12325-020-01255-8
M3 - Article
C2 - 32157626
AN - SCOPUS:85081883742
SN - 0741-238X
VL - 37
SP - 1608
EP - 1619
JO - Advances in Therapy
JF - Advances in Therapy
IS - 4
ER -